Robert W. Hoffman

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace, Richard Furie, Yoshiya Tanaka et al. · The Lancet · 2018 · 497 citations · Full text

Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Treatment, Lupus +8

Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings

Mark A. Burdt, Robert W. Hoffman, Susan L. Deutscher et al. · Arthritis & Rheumatism · 1999 · 375 citations

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

James G. Krueger, Scott Fretzin, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology · 2012 · 370 citations · Full text

Inflammation, Cytokine, Cell Activation +12

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

Pilar Pérez, Robert W. Hoffman, Stephen Shaw et al. · Nature · 1985 · 338 citations

Cancer Immunosurveillance, Cytotoxic T Cells, T-regulatory Cell +11

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

David Isenberg, Michelle Petri, Kenneth Kalunian et al. · Annals of the Rheumatic Diseases · 2015 · 227 citations · Full text